Publications

• Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning
  Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., & Lowsky, R. (2015). Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. BONE MARROW TRANSPLANTATION, 50(10), 1286-1292.
• Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study
  Anderlini, P., Wu, J., Gersten, I., Ewell, M., Tolar, J., & Eapen, M. (2015). Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. LANCET HAEMATOLOGY, 2(9), E367-E375.
• Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease
  Palmer, J., Chai, X., Martin, P. J., Weisdorf, D., Inamoto, Y., & Lee, S. J. (2015). Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. HAEMATOLOGICA, 100(5), 690-695.
• Outcomes After Heart Transplantation for Amyloid Cardiomyopathy in the Modern Era Davis, M. K., Kale, P., Liedtke, M., Schrier, S., Arai, S., & Witteles, R. M. (2015). Outcomes After Heart Transplantation for Amyloid Cardiomyopathy in the Modern Era. AMERICAN JOURNAL OF TRANSPLANTATION, 15(3), 650-658.
  
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., & Flowers, M. Ed. (2015). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biology of blood and marrow transplantation , 21(3), 389-401 e1.
  
• Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Arai, S., Arora, M., Wang, T., Spellman, S. R., He, W., & Pavletic, S. Z. (2015). Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biology of blood and marrow transplantation , 21(2), 266-274.
  
• Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease Inamoto, Y., Martin, P. J., Storer, B. E., Palmer, J., Weisdorf, D. J., & Lee, S. J. (2014). Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. HAEMATOLOGICA, 99(10), 1618-1623.
  
• Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Inamoto, Y., Martin, P. J., Storer, B. E., Palmer, J., Weisdorf, D. J., & Lee, S. J. (2014). Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Haematologica, 99(10), 1618-1623.
  
• Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., & Lowsky, R. (2014). Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(6), 837-843.
  
• Assessment of Joint and Fascia Manifestations in Chronic Graft-Versus-Host Disease Inamoto, Y., Pidala, J., Chai, X., Kurland, B. F., Weisdorf, D., & Carpenter, P. A. (2014). Assessment of Joint and Fascia Manifestations in Chronic Graft-Versus-Host Disease. ARTHRITIS & RHEUMATOLOGY, 66(4), 1044-1052.
  
• Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease Palmer, J., Williams, K., Inamoto, Y., Chai, X., Martin, P. J., & Lee, S. J. (2014). Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(3), 337-344.
  
• Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., & Witteles, R. M. (2014). Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. HEART RHYTHM, 11(1), 158-162.
  
• Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. Weng, W.-K., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., & Kim, Y. H. (2013). Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. Science translational medicine, 5(214), 214ra171-?.
  
• Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma Weng, W.-K., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., & Kim, Y. H. (2013). Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma. SCIENCE TRANSLATIONAL MEDICINE, 5(214).
  
• Comorbidity burden in patients with chronic GVHD Wood, W. A., Chai, X., Weisdorf, D., Martin, P. J., Cutler, C., & Mitchell, S. (2013). Comorbidity burden in patients with chronic GVHD. BONE MARROW TRANSPLANTATION, 48(11), 1429-1436.
  
• Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., & Liedtke, M. (2013). Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. HAEMATOLOGICA, 98(10), 1593-1599.
  
• Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium Treister, N., Chai, X., Kurland, B., Pavletic, S., Weisdorf, D., & Cutler, C. (2013). Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium. BONE MARROW TRANSPLANTATION, 48(8), 1123-1128.
  
• The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., & Liedtke, M. (2013). The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 161(3), 367-372.
  
• H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease Sahaf, B., Yang, Y., Arai, S., Herzenberg, L. A., Herzenberg, L. A., & Miklos, D. B. (2013). H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(8), 3005-3010.
  
• Successful Surgical and Medical Treatment of Rhizopus Osteomyelitis Following Hematopoietic Cell Transplantation Vashi, N., Avedian, R., Brown, J., & Arai, S. (2012). Successful Surgical and Medical Treatment of Rhizopus Osteomyelitis Following Hematopoietic Cell Transplantation. ORTHOPEDICS, 35(10), E1556-E1561.
  
• Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium Jacobsohn, D. A., Kurland, B. F., Pidala, J., Inamoto, Y., Chai, X., & Flowers, M. Ed. (2012). Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. BLOOD, 120(13), 2545-2552.
  
• Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels Tolar, J., Deeg, H. J., Arai, S., Horwitz, M., Antin, J. H., & Anderlini, P. (2012). Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(7), 1007-1011.
  
• Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., & Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145-6154.
  
• More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis Stevenson, R., Witteles, R., Damrose, E., Arai, S., Lafayette, R. A., & Liedtke, M. (2012). More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 138(5), 509-511.
  
• Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., & Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581-588.
  
• Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., & Stockerl-Goldstein, K. (2012). Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. BONE MARROW TRANSPLANTATION, 47(4), 516-521.
  
• Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study Pidala, J., Vogelsang, G., Martin, P., Chai, X., Storer, B., & Lee, S. J. (2012). Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(3), 451-458.
  
• Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2012). Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 31(3), 325-331.
  
• Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., & Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679-1687.
  
• A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies Chen, G. L., Arai, S., Flowers, M. Ed., Otani, J. M., Qiu, J., & Miklos, D. B. (2011). A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. BLOOD, 118(15), 4070-4078.
  
• Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria Arai, S., Jagasia, M., Storer, B., Chai, X., Pidala, J., & Lee, S. J. (2011). Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. BLOOD, 118(15), 4242-4249.
  
• Short tandem repeat and human leukocyte antigen mutations or losses confound engraftment and typing analysis in hematopoietic stem cell transplants Pereira, S., Vayntrub, T., Hiraki, D. D., Cherry, A. M., Arai, S., & Grumet, F. C. (2011). Short tandem repeat and human leukocyte antigen mutations or losses confound engraftment and typing analysis in hematopoietic stem cell transplants. HUMAN IMMUNOLOGY, 72(6), 503-509.
  
• Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen Schaenman, J. M., Shashidhar, S., Rhee, C., Wong, J., Navato, S., & Brown, J. M. (2011). Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(5), 693-702.
  
• Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium Pidala, J., Kurland, B., Chai, X., Majhail, N., Weisdorf, D. J., & Lee, S. J. (2011). Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. BLOOD, 117(17), 4651-4657.
  
• Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., & Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192-199.
  
• Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia Jones, C. D., Arai, S., Lowsky, R., Tyan, D. B., Zehnder, J. L., & Miklos, D. B. (2010). Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 150(5), 637-639.
  
• Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., & Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145-1154.
  
• Rituximab in hematopoietic cell transplantation Arai, S., & Miklos, D. B. (2010). Rituximab in hematopoietic cell transplantation. EXPERT OPINION ON BIOLOGICAL THERAPY, 10(6), 971-982.
  
• TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., & Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099-1109.
  
• High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation Majhail, N. S., Flowers, M. E., Ness, K. K., Jagasia, M., Carpenter, P. A., & Burns, L. J. (2009). High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 43(1), 49-54.
  
• Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial Arai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., & Klingemann, H. (2008). Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. CYTOTHERAPY, 10(6), 625-632.
  
• A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer Kurian, A. W., Newton Thompson, R., Gaw, A. F., Arai, S., Ortiz, R., & Garber, A. M. (2007). A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 25(6), 634-641.
  
• Natural killer cells: can they be useful as adoptive immunotherapy for cancer? Arai S, & Klingemann H-G. (2005). Natural killer cells: can they be useful as adoptive immunotherapy for cancer?. Expert Opin Biol Ther.
  
• Regulation of OX40 gene expression in graft-versus- host disease Miura, Y., Thoburn, C. J., Bright, E. C., Arai, S., & Hess, A. D. (2005). Regulation of OX40 gene expression in graft-versus- host disease. TRANSPLANTATION PROCEEDINGS, 37(1), 57-61.
  
• Association of Foxp3 regulatory gene expression and graft-versus-host disease Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, & Hess AD. (2004). Association of Foxp3 regulatory gene expression and graft-versus-host disease. Blood, 104.
  
• Role of immunotherapy in stem cell transplantation Arai, S., & Klingemann, H. G. (2003). Role of immunotherapy in stem cell transplantation. INTERNATIONAL JOURNAL OF HEMATOLOGY, 77(1), 22-28.
  
• Poor outcome in steroid refractory GVHD with ATG treatment Arai S, Margolis J, Zahurak M, Anders V, & Vogelsang GB. (2002). Poor outcome in steroid refractory GVHD with ATG treatment. Biol Blood Marrow Transplant, 8.
  
• Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings Vogelsang, G. B., & Arai, S. (2001). Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. BONE MARROW TRANSPLANTATION, 27(12), 1255-1262.
  
• von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy Arai S, Allan C, Streiff M, Hutchins GM, Vogelsang GB, & Tsai HM. (2001). von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. The Hematology Journal, 2.
  
• Management of graft-versus-host disease Arai, S., & Vogelsang, G. B. (2000). Management of graft-versus-host disease. BLOOD REVIEWS, 14(4), 190-204.